Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients. In PAH patients, phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment, with the more-efficacious prostacyclin therapies used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only approved therapy for CTEPH patients. PH is a highly lucrative market despite the relatively small patient population.
- What is the current patient share of branded therapies such as United Therapeutics' Orenitram and Remodulin, Actelion’s Opsumit, and Bayer’s Adempas?
- What effect has the launch of Actelion’s Uptravi had on treatment decisions?
- What are the anticipated changes in prescribing patterns over the next 12 months?
- How are specialists utilizing PAH therapies for the treatment of PH WHO Groups 2-5?
- What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of PH?
- What are the drivers and constraints determining prescribing practices for PH?
- Geography: United States
- Primary Research: Survey of 101 U.S. cardiologists / pulmonologists
- Key Drugs Covered: Uptravi, Opsumit, Remodulin, Tyvaso, Orenitram, Adempas, sildenafil, tadalafil, iloprost, epoprostenol
- Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights - Pulmonary Hypertension - US - June 2019